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Germline mutations in the gene encoding phosphatase and tensin homolog deleted on chromosome ten (PTEN [MIM 601728]) are
associated with a number of clinically distinct heritable cancer syndromes, including both Cowden syndrome (CS) and Bannayan-Riley-
Ruvalcaba syndrome (BRRS). Seemingly identical pathogenic PTENmutations have been observed in patients with CS and BRRS, as well
as in patients with incomplete features of CS, referred to as CS-like (CSL) patients. These observations indicate that additional, uniden-
tiﬁed, genetic and epigenetic factors act as phenotypic modiﬁers in these disorders. These genetic factors could also contribute to disease
in patients with CS, CSL, or BRRS without identiﬁable PTENmutations. Two potential modiﬁers aremiR-19a andmiR-21, which are pre-
viously identiﬁed PTEN-targeting miRNAs. We investigated the role of these miRNAs by characterizing their relative expression levels in
PTEN-mutation-positive and PTEN-mutation-negative patients with CS, CSL, or BRRS. Interestingly, we observed differential expression
of miR-19a and miR-21 in our PTEN-mutation-positive patients. Both were found to be signiﬁcantly overexpressed within this group
(p < 0.01) and were inversely correlated with germline PTEN protein levels. Similarly, the relative expression of miR-19a and miR-21
was differentially expressed in a series of PTEN-mutation-negative patients with CS or CSL with variable clinical phenotypes and
decreased full-length PTEN protein expression. Among PTEN-mutation-positive patients with CS, both miRNAs were signiﬁcantly over-
expressed (p¼ 0.006–0.013). Taken together, our study results suggest that differential expression of PTEN-targetingmiR-19a andmiR-21
modulates the PTEN protein levels and the CS and CSL phenotypes, irrespective of the patient’s mutation status, and support their roles
as genetic modiﬁers in CS and CSL.Introduction
Cowden syndrome (CS [MIM 158350]) is an underdiag-
nosed autosomal-dominant disorder characterized by
multiple hamartomatous lesions and a vast phenotypic
spectrum that includes predisposition to malignancies of
the breast, thyroid, and endometrium.1 The majority of
patients with CS (85%) have been found to harbor patho-
genic germline mutations in the gene encoding phospha-
tase and tensin homolog deleted on chromosome ten
(PTEN [MIM 601728]), a tumor-suppressor gene located
on 10q23.2 The inactivation of PTEN protein, an antago-
nist of the phosphatidylinositol-triphosphate kinase
(PI3K)-signaling pathway, in CS results in the constitutive
activation of Akt.3–8 As a consequence, hyperactive Akt-
mediated signaling of several cascades results in increased
and uncontrolled cellular survival and proliferation.
Germline mutations in PTEN also cause a subset of Ban-
nayan-Riley-Ruvalcaba syndrome (BRRS [MIM 153480]),
a related hamartomatous tumor syndrome that shares, in
addition to its genetic etiology, a few of the clinical mani-
festations seen in CS.3 Interestingly, identical pathogenic
PTEN mutations have been observed among patients
with these seemingly disparate disorders.9 Furthermore,
these same identical mutations have also been observed
in two additional hamartomatous tumor syndromes,
Proteus syndrome (PS [MIM 176920]) and Proteus-like syn-
drome (PLS), as well as in a subset of patients referred to as
CS-like (CSL) patients who do not meet the full diagnostic
criteria for CS.1,3 Whereas germline PTEN mutations haveThe Ambeen identiﬁed in the majority of patients diagnosed with
CS and BRRS, for approximately 15% and 35%, respec-
tively, as well as for 90% of patients with CSL, the patho-
genic mutations have yet to be identiﬁed.2,9 Interestingly,
decreased PTEN protein expression has been observed in
a large number of these PTEN-mutation-negative patients
(Waite and Eng, unpublished observation). The lack of
detectable germline PTENmutations in subsets of patients
with CS, CSL, or BRRS with altered PTEN protein expres-
sion, as well as the imprecise genotype-phenotype correla-
tion associated with these syndromes, suggests the pres-
ence of alternate mechanisms that contribute to PTEN
dysfunction and to the development and progression of
the disease.
MicroRNAs (miRNAs), a novel class of negative gene
regulators, have recently been shown to regulate the ex-
pression of several tumor suppressors and oncogenes and
contribute to carcinogenesis.10–14 To date, two miRNAs,
miR-19a andmiR-21, have been reported to speciﬁcally tar-
get and to downregulate PTEN.15,16 Furthermore, the over-
expression of each of these miRNAs has been correlated
with decreased PTEN levels in human cancer.17,18
Because PTEN dysfunction is common in patients with
CS, CSL, and BRRS, irrespective of their mutation status,
we hypothesized that aberrant miR-19a and/or miR-21
expression could modulate PTEN protein levels and,
thereby, modulate phenotypic expression in patients
with these syndromes. To investigate this hypothesis, we
chose to characterize the relative expression levels of
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PTEN-mutation-negative patients with CS, CSL, and BRRS
relative to healthy control subjects.
Subjects and Methods
Study Subjects
A total of 178 unrelated subjects were included in the present
study, including 20 control subjects and 158 patients with CS,
CSL, or BRRS (Table 1). Mutation analysis of the entire PTEN cod-
ing sequence and its exon-intron boundaries and promoter region
was performed for all patients with CS, CSL, or BRRS who were in-
cluded in the present study.2 Additionally, all patient samples were
also screened for PTEN protein expression by Western blot analy-
sis. Brieﬂy, patient protein lysates were isolated from immortalized
lymphoblastoid cell lines (LBCLs) by the GenomicMedicine Biore-
pository and protein concentrations were determined by use of
the BCA assay, with BSA as a standard. Thirty micrograms of
protein was applied to nitrocellulose with a dotblot apparatus
(Bio-Rad, Hercules, CA, USA). Equal protein loading was con-
ﬁrmed by staining of the nitrocellulose blots with Ponceau stain
(Bio-Rad). Nitrocellulose blots were then subjected to Western
blot analysis with a-PTEN (monoclonal antibody clone 6H2.1,
Cascade Biosciences, Portland, OR, USA) at 1:1000 dilution and
then incubated with appropriate secondary antibody as previously
described.7 Proteins were visualized via enhanced chemilumines-
cence. Full-length PTEN protein levels were compared to controls
and scored by two individuals as either normal, decreased (<50%
loss, compared to controls), half (~50% of controls), or faint
(>50% loss, compared to controls). PTEN-mutation-negative










Male 7 (35.0) 12 (42.9) 10 (7.7)
Female 13 (65.0) 16 (57.1) 120 (92.3)
Phenotype
CS – 17 (60.7)b 63 (48.5)
CSL – 5 (17.9) 62 (47.7)
BRRS – 5 (17.9) 5 (3.8)
Mutation
R130X – 13 (46.4) –
R233X – 5 (17.9) –
R335X – 10 (35.7) –
Clinical Features
Macrocephaly – 25 (89.3) 53 (40.8)
Pathognomonic – 16 (57.1) 28 (21.5)
Breast CA – 7 (43.8)c 80 (66.7)c
Thyroid CA – 2 (7.1) 32 (24.6)
Endometrial CA – 2 (12.5)c 14 (11.7)c
Pathognomonic features include the mucocutaneous lesions associated
with CS (trichilemmomas, acral keratoses, and papillomatous papules).
a Values are expressed as n (%).
b One PTEN-mutation-positive sample had features consistent with both CS
and BRRS.
c Frequency among female patients.1142 The American Journal of Human Genetics 82, 1141–1149, Maypatients with decreased, half, or faint full-length PTEN protein
levels were also scanned for large deletions and rearrangements,
and those with the latter were excluded. Among the patients
with CS, CSL, or BRRS, 28/158 of the individuals selected for inclu-
sion were previously found to harbor pathogenic germline muta-
tions (i.e., mutation-positive patients). Mutation analysis in the
remaining 130/158 patients revealed no detectable germline
PTEN mutations (i.e., mutation-negative patients). For interroga-
tion of miR-19a and miR-21 expression in patients with CS, CSL,
or BRRS without germline PTEN mutations but with deregulated
PTEN protein levels, all 130 mutation-negative patients selected
for inclusion in the current study were previously found to have
decreased full-length PTEN protein expression relative to normal
controls (data not shown). All subjects were enrolled by referral
from centers throughout the United States, Canada, and Europe
after granting informed consent in accordance with procedures
approved by the human-subjects-protection committees of each
respective institution.
Among the cohort of PTEN-mutation-positive patients included
in our analysis were 13/28 patients with R130X mutations (c.388
C/T), 5/28 patients with R233X mutations (c.697 C/T), and 10/28
patients with R335Xmutations (c.1003 C/T) (Figure 1 and Table 1).
Of those patients with R130Xmutations, 9/13 had classic CS, 1/13
exhibited a CSL phenotype, and 2/13 had classic BRRS. Addition-
ally, 1/13 patients with an R130X mutation had phenotypic
features consistent with both CS and BRRS, and this patient thus
was considered as a CS/BRRS overlap patient. Among the patients
with an R233Xmutation, 1/5 met classic CS criteria, 3/5 were con-
sidered as having CSL, and 1/5 had classic BRRS. Lastly, of patients
with R335Xmutations, 7/10 met classic CS criteria, 1/10 had CSL,
and 2/10 had BRRS.
Among the cohort of PTEN-mutation-negative patients with
decreased full-length PTEN expression, 63/130 had classic CS,
62/130 had CSL, and 5/130 were diagnosed with BRRS. All muta-
tion-positive and mutation-negative patients with CS included in
the present study were classiﬁed in accordance with criteria estab-
lished by the International Cowden Consortium and incorporated
into the practice guidelines of the National Comprehensive
Cancer Network.1
Cell Lines and Culture
LBCLs from all healthy control samples and those from patients
with CS, CSL, or BRRS were generated by the Genomic Medicine
Biorepository. LBCLs were cultured in RPMI-1640 media supple-
mented with 20% FBS and 100 units/ml each of Penicillin and
Streptomycin and maintained at 37C with 5% CO2.
Isolation of Total RNA and cDNA Synthesis
Total RNA was isolated from control and patient LBCLs with the
miRVana miRNA Isolation Kit (Ambion, Austin, TX, USA) accord-
ing to the manufacturer’s protocol and, subsequently, subjected
to DNase treatment with DNA-free (Ambion). For analysis of
PTEN expression levels, 1 mg of DNase-treated RNA was converted
to cDNA with Superscript II Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA) as speciﬁed by the manufacturer.
In order to assay mature miR-19a and miR-21 expression in our
control and patient samples, stem-loop reverse transcription (RT)
was performed with TaqMan MicroRNA Assays (Applied Biosys-
tems, Foster City, CA). For each miRNA, individual RT reactions
were carried out with 10 ng of DNase-treated RNA and either
miR-19a-, miR-21-, or U6 small nuclear RNA (RNU6)-speciﬁc2008
Figure 1. Schematic Diagram of PTEN’s
mRNA Sequence
PTEN’s full-length mRNA sequence
(NM_000314.4), including its 1032 nucle-
otide (nt) 50 UTR, 1212 nt coding se-
quence, and 3302 nt 30 UTR, is shown along
with the miR-19a binding site (position
*1208 to *1228). miR-21’s binding site
has not been reported. Additionally, the positions for the three truncating mutations R130X, R233X, and R335X are shown. PTEN’s
translation start site and the region encoding PTEN’s phosphatase core are also annotated.TaqMan MicroRNA RT primers (Applied Biosystems). Twenty-mi-
croliter RT reactions were performed with the TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystems) according to the
manufacturer’s protocol.
Real-Time Quantitative PCR
Relative expression of the full-length PTEN transcript was assayed for
all samples with 12.5 ml SYBR Green PCR Master Mix (Applied Bio-
systems), 10 mM forward primer (50-TCCACAAACAGAACAAGAT
G-30), 10 mM reverse primer (50-CTGGTCCTGGTATGAAGAAT-30),
and 20 ng of template cDNA. Thermal cycling conditions comprised
50C for 2 min, 95C for 10 min, and 40 cycles at 95C for 15 s
followed by 60C for 1 min with an ABI 7500 Sequence Detection
System (Applied Biosystems). Real-time PCR reactions were also
performed for GAPDH, a normalization control (F: 50-GGGCT
GCTTTTAACTCTGGTAA-30 and R: 50-ATGGGTGGAATCATATTG
GAAC-30).
MaturemiR-19a andmiR-21 expression was assayed with a 20 ml
reaction containing 10.0 ml TaqMan 2XUniversal PCRMasterMix,
No AmpErase UNG (Applied Biosystems), 1.0 ml 20X TaqMan
MicroRNA assay (Applied Biosystems), and 1.3 ml of RT product.
Real-time PCR conditions were performed as follows: 50C for
2 min, 95C for 10 min, and 40 cycles at 95C for 15 s followed
by 60C for 1 min with an ABI 7500 Sequence Detection System
(Applied Biosystems). Additionally, RNU6 expression was assayed
for normalization.
All reactions were performed in triplicate, and relative gene-
expression determinations were made with the comparative
delta-delta CT method (2
DDCT) as described by Livak et al.19
Statistical Analysis
After expression analysis was performed, statistical comparisons of
relative levels of PTEN, miR-19a, and miR-21 expression between
all patient groups and control samples were performed with
Welch’s t test. All results were considered signiﬁcant at the p <
0.05 level. In addition, we performed classiﬁcation and regression
tree (CART) analysis as implemented in the R software package.
Results
Differential Expression of miR-19a and miR-21
in Three Groups of Patients with CS, CSL, or BRRS
withGermlinePTENMutationR130X,R233X,orR335X
In the present study, we sought to investigate whether
miRNAs previously shown to target and regulate PTEN pro-
tein expression are differentially regulated in patients with
CS, CSL, and BRRS relative to healthy controls and, more
speciﬁcally, whether these miRNAs are modiﬁers of these
phenotypes. To address this question, we initially choseThe Amto assess the relative expression of miR-19a and miR-21 in
a series of 28 PTEN-mutation-positive patients sharing
identical truncating mutations located in each of PTEN’s
three most frequently mutated exons (Figure 1) and in 20
normal controls.3 Included among these patients were 13
carriers of R130X mutations, ﬁve carriers of R233X muta-
tions, and ten carriers of R335X mutations. Previous stud-
ies have reported a broad clinical spectrum in patients even
within each of these three mutation groups.9,20 Similar ob-
servations were apparent in this collection, given that nine
patients with CS, one with CSL, one with CS and BRRS,
and two with BRRS were among those with R130X muta-
tions; one patient with CS, three with CSL, and one with
BRRS were among those with R233Xmutations; and seven
patients with CS, one with CSL, and two with BRRS were
among those with R335X mutations (Table S1, available
online).
In addition to the variable clinical spectrum observed
among patients with identical mutations, levels of PTEN
mRNA expression were also found to be variable. Among
all 28 PTEN-mutation-positive patients, expression of
PTEN transcript levels were signiﬁcantly reduced relative
to controls (p ¼ 0.015) (Table 2). However, when we di-
vided this group on the basis of the three different germ-
line PTENmutations found in these patients, signiﬁcantly
decreased PTEN transcript expression was only observed in
patients with the R130X and R233Xmutations (p < 0.001)
(Table 2) and not in carriers of the R335X mutation (p ¼
0.287). Similarly, we observed differential expression of
miR-19a andmiR-21 among our mutation-positive samples.
Overall, the average relative expression of both miR-19a
andmiR-21 was higher in mutation-positive patients com-
pared to controls (2DDCT ¼ 1.54 versus 1.08, p ¼ 0.003;
and 2DDCT ¼ 1.49 versus 1.15, p ¼ 0.006, respectively)
(Figure 2A and Table 2). For mutation-positive patients
with R130X and R233X mutations, miR-19a was found to
be overexpressed as compared to that of controls (p ¼
0.037 and p ¼ 0.015, respectively), whereas miR-21 was
overexpressed only in carriers of the R130X mutation
(p ¼ 0.044). miR-19a and miR-21 were not differentially
expressed in carriers of the R335X mutation relative to
our control population. Interestingly, 90% of patients
with this mutation had decreased full-length PTEN protein
levels, compared to only 54% of those with R130X muta-
tions. Moreover, although miR-19a and miR-21 were not
differentially expressed in carriers of the R335X mutation,
the majority of these patients (70%) exhibit classic CSerican Journal of Human Genetics 82, 1141–1149, May 2008 1143
features, compared to only 56% of patients with R130X
and/or R233X mutations.
miR-19a and miR-21 Overexpression are Associated
with Decreased Full-Length PTEN Protein Levels and
Clinical Phenotype in PTEN-Mutation-Positive
Patients with CS, CSL, or BRRS
Our data show that PTEN transcript and PTEN protein
levels, as determined by Western blot analysis, do not
correspond well among many of the mutation-positive
patients included in this analysis, suggesting that other bi-
ological processes are likely involved in the regulation of
these products (Table S1). On the basis of this observation,
we then chose to examine the relationship between the
relative expression of each miRNA and PTEN protein levels
in these patients. More speciﬁcally, we examined levels of
miR-19a and miR-21 expression in mutation-positive pa-
tients with normal full-length PTEN protein expression
compared to those with decreased full-length PTEN pro-
tein levels. Interestingly, both miRNAs were signiﬁcantly
overexpressed in PTEN-mutation-positive patients with
decreased full-length PTEN protein levels as compared
Table 2. Summary of Comparisons of Relative Levels of PTEN
Transcript, miR-19a, and miR-21 Expression among Control
Samples and PTEN-Mutation-Positive and PTEN-Mutation-
Negative Patient and Patient Subgroup Samples
PTEN miR-19a miR-21
PTENþ 0.015 0.003 0.006
R130X ! 0.001 0.037 0.044
R233X ! 0.001 0.015 0.184
R335X 0.287 0.137 0.147




PTENþ CS 0.069 0.006 0.013
PTENþ CSL 0.055 0.034 0.085
PTENþ BRRS 0.209 0.932 0.772
PTEN 0.969 ! 0.001 0.141
PTEN CS 0.900 ! 0.001 0.835
PTEN CSL 0.544 ! 0.001 0.018
PTEN BRRS 0.148 0.492 0.215
PTENþ versus PTEN 0.001 0.977 ! 0.001
PTENþ CS versus PTEN CS 0.020 0.878 0.015
PTENþ CSL versus PTEN CSL 0.079 0.368 0.029
PTENþ BRRS versus PTEN BRRS 0.067 0.496 0.326
p values were determined from t tests comparing the relative expression
of PTEN, miR-19a, and miR-21 between controls and patients or patient
subgroups, except where indicated. Significant results are indicated as
underlined.
‘‘PTENþ’’ denotes PTEN-mutation-positive patients.
‘‘PTEN’’ denotes PTEN-mutation-negative patients.
‘‘PTENþ dec.’’ denotes PTENþ patients with decreased PTEN protein expres-
sion. PTEN protein status ‘‘calls’’ are illustrated in Figure S1.
‘‘PTENþ norm.’’ denotes PTENþ patients with normal PTEN protein expres-
sion. PTEN protein status ‘‘calls’’ are illustrated in Figure S1.
‘‘R130X/R233X dec.’’ denotes patients with R130X and/or R233X mutations
with decreased PTEN protein expression.
‘‘R130X/R233X norm.’’ denotes patients with R130X and/or R233X muta-
tions with normal PTEN protein expression.1144 The American Journal of Human Genetics 82, 1141–1149, Mato those with normal full-length PTEN protein levels
(miR-19a: 2DDCT ¼ 1.69 versus 1.13, p ¼ 0.009; miR-21:
2DDCT ¼ 1.65 versus 1.07, p ¼ 0.003, respectively) (Fig-
ure 2B and Table 2). Moreover, patients with R130X and/
or R233X mutations with decreased full-length PTEN pro-
tein expressed approximately 54%higher levels ofmiR-19a
(p¼ 0.020) and 60%higher levels ofmiR-21 (p¼ 0.008) rel-
ative to patients with R130X and/or R223X mutations
with normal PTEN protein levels (Table 2).
Next, we subdivided our PTEN-mutation-positive group
on the basis of their clinical diagnoses (CS, CSL, or BRRS)
and compared their relative levels of miR-19a,miR-21, and
PTEN expression to those of the control group. Mutation-
positive patients with CS displayed relative overexpression
of both miR-19a and miR-21 compared to controls (p ¼
0.006 and p ¼ 0.013, respectively) (Figure 2C and Table 2).
A modest association was observed between the muta-
tion-positive group of patients with CSL and miR-19a ex-
pression status (p¼ 0.034), whereasmiR-21 overexpression
in this same group did not reach statistical signiﬁcance
when compared to controls (p ¼ 0.085), which was due in
part to the small sample size in this latter subgroup. No
differences in PTEN transcript expression were observed
in either phenotypic subgroup. Lastly, PTEN transcript,
miR-19a, and miR-21 expression did not differ between
the mutation-positive patients with BRRS and the controls
(p > 0.20).
Additionally, PTEN transcript, miR-19a, and miR-21 ex-
pression did not differ between PTEN-mutation-positive
patients with CS and PTEN-mutation-positive patients
with CSL (p > 0.200). Both miR-19a and miR-21 levels
were lower in patients with BRRS as compared to levels
in patients with CS (miR-19a: 2DDCT ¼ 1.07 versus 1.63
and miR-21: 2DDCT ¼ 1.25 versus 1.53) and in patients
with CSL (miR-19a: 2DDCT ¼ 1.07 versus 1.67 and
miR-21: 2DDCT ¼ 1.25 versus 1.56), although statistical
signiﬁcance was only reached in comparisons of miR-19a
expression (p < 0.05).
Differential Expression of miR-19a and miR-21
in PTEN-Mutation-Negative Patients
with CS, CSL, or BRRS
Differential expression of miR-19a and miR-21 in PTEN-
mutation-positive patients with CS, CSL, or BRRS with var-
iable PTEN protein expression suggests that these miRNAs
play a role in modulation of both the PTEN protein expres-
sion and the disease phenotype in patients with these
syndromes. On the basis of these results, we further hy-
pothesized that these miRNAs could play a similar role in
patients with CS, CSL, or BRRS who lack detectable PTEN
mutations. To investigate this, we chose, therefore, to
assess the relative expression of miR-19a and miR-21 in
130 selected patients with CS, CSL, or BRRS with both
undetectable PTEN mutations and decreased full-length
PTEN protein expression.
In contrast to the PTEN-mutation-positive patients,
decreased expression of PTEN transcript levels was noty 2008
Figure 2. Relative Expression Values for PTEN Transcript, miR-19a, and miR-21 in PTEN-Mutation-Positive Patients
Relative expression values for PTEN transcript and each miRNA are shown for (A) controls and all mutation-positive patients, (B) muta-
tion-positive patients who express normal PTEN protein and those who express decreased PTEN protein, and (C) controls and mutation-
positive patients subdivided on the basis of their clinical phenotypes.
All relative expression values are expressed as n-fold change (2DDCT).
PTENþ ¼ PTEN-mutation-positive patients.observed in mutation-negative patients (p ¼ 0.969). Inter-
estingly, similar to our mutation-positive patients, muta-
tion-negative patients displayed relative overexpression
of miR-19a as compared to our control population (p <
0.001) (Figure 3 and Table 2). However, contrary to what
was observed in mutation-positive patients, no difference
in miR-21 expression was observed in this group (p ¼
0.141).
Following this analysis, PTEN-mutation-negative pa-
tients were subsequently subdivided on the basis of their
clinical diagnoses (CS, CSL, or BBRS). We then carried
out analyses of genotype-phenotype association based
on these groupings. Similar to the mutation-positive co-
hort, miR-19a overexpression was observed both in muta-
tion-negative patients with CS and in mutation-negative
patients with CSL (p < 0.001 in both groups) (Table 2).
In contrast, miR-21 was underexpressed in mutation-
negative patients with CSL compared to controls (p ¼
0.018), whereas no difference was observed in patients
with CS from this same group (p ¼ 0.835). We did not
detect any difference in miR-19a and miR-21 expression
among our mutation-negative patients with BRRS (p >
0.215).
miR-21 is Differentially Expressed
between PTEN-Mutation-Positive
and PTEN-Mutation-Negative Patients
Because miR-19a is overexpressed in patients with CS or
CSL irrespective of PTEN mutation status, whereas over-
expressed miR-21 occurs only in PTEN-mutation-positive
patients, we then chose to compare the relative expression
of each miRNA between patients with and without PTEN
mutations. miR-21 was signiﬁcantly overexpressed in
PTEN-mutation-positive patients relative to patients with-
out PTENmutations (2DDCT¼ 1.48 versus 1.05, p< 0.001)The Am(Figure 3 and Table 2), whereasmiR-19a expression did not
differ between the two groups (p ¼ 0.977). PTEN transcript
levels were signiﬁcantly lower in the mutation-positive pa-
tient group (p ¼ 0.001). When subdivided on the basis of
their clinical diagnoses, miR-21 overexpression was ob-
served both in groups of mutation-positive patients with
CS and in groups of mutation-positive patients with CSL
relative to mutation-negative patients with these same
phenotypes (p ¼ 0.015 and p ¼ 0.029, respectively),
whereas miR-19a expression did not differ among these
subgroups (p > 0.50).
miR-21 Expression Could Contribute to Phenotypic
Features Associated with CS
To investigate whether differential expression of miR-19a
and miR-21 was associated with the cancers commonly
seen in CS, as well as with other clinical features of the syn-
drome, we compared their relative expression between pa-
tient groups with and without each of the key phenotypic
features of CS. These comparisons failed to yield any signif-
icant associations with breast cancer, thyroid cancer, or
macrocephaly between miRNA or PTEN expression among
all patient samples and patient subgroups (p > 0.05), prob-
ably due to small sample sizes in subgroup analyses.We did
observe a trendofoverexpressionofmiR-21 inpatientsdiag-
nosed with endometrial cancer as compared to those not
diagnosed with this cancer, irrespective of mutation status
(2DDCT ¼ 1.39 versus 1.06 for PTEN-mutation-positive pa-
tients and 2DDCT ¼ 1.37 versus 1.01 for PTEN-mutation-
negative patients; p¼ 0.12-0.15). Despite our small sample
size,wedidﬁnd thatmiR-21was signiﬁcantlyoverexpressed
among patients with CS and one or more pathognomonic
feature (adult Lhermitte-Duclos disease, trichilemmomas,
acral keratoses, andpapillomatouspapules) relative to those
without any of these features (p ¼ 0.02).erican Journal of Human Genetics 82, 1141–1149, May 2008 1145
To examine the predictive value each miRNA might
contribute to the CS phenotypes observed in PTEN-muta-
tion-negative patients, we performed CART analysis in an
attempt to identify subgroups of patients at higher risk of
developing four major clinical features associated with
this syndrome (breast cancer, endometrial cancer, thyroid
cancer, and macrocephaly) by using relative expression
values for bothmiR-19a andmiR-21. Additional CARTanal-
ysiswas performed for theCS andCSLphenotypes. Approx-
imately 76% of mutation-negative patient samples with
relative miR-19a expression > 2.26 had developed breast
cancer. Similarly, 70%of thosewithhighmiR-21 expression
(2DDCT> 1.81) also developed breast cancer. Although the
total number ofmutation-negative patients included in our
studywhodevelopedendometrial cancerwas small (N¼16),
noneof these patientswere among the subgroups identiﬁed
with relatively lowmiR-19a andmiR-21 expression (2DDCT
< 0.87 and < 0.64, respectively).
Macrocephaly was observed in 64% of PTEN-mutation-
negative patients with miR-19a expression > 2.60, and
this feature was observed in 71% of patients with miR-21
expression > 1.94. Analysis of the CS and CSL phenotypes
revealed that 72% of mutation-negative patients with high
miR-19a expression (2DDCT > 2.32) had classic CS,
whereas 67% of those with low miR-19a expression
(2DDCT < 0.75) had CSL. Similarly, 79% of patients with
high miR-21 expression (2DDCT > 1.56) had CS. CART
analysis was not able to identify any unique clusters of pa-
tients with thyroid cancer among the mutation-negative
patients with the use of either miRNA as a predictor.
Each phenotype was also assessed with the use of the
relative expression of both miRNAs jointly as phenotypic
predictors. Although expression of neither miRNAwas pre-
dictive of thyroid cancer, as was the case when each was
Figure 3. Relative Expression Values for PTEN Transcript,
miR-19a, and miR-21 among PTEN-Mutation-Positive
Patients, PTEN-Mutation-Negative Patients, and Controls
All relative expression values are expressed as n-fold change
(2DDCT).
considered separately, high miR-21 expression proved
to be the single strongest predictor for endometrial can-
cer, macrocephaly, and the CS or CSL phenotype given
that the joint analysis with both miR-19a and miR-21
together identiﬁed the same clusters as did miR-21
considered independently.
Discussion
Alternate mechanisms of PTEN dysfunction are becom-
ing increasingly germane in the PTEN hamartoma tu-
mor syndromes, particularly in CS and BRRS.21–24 Our
investigation of two PTEN-targeting miRNAs, miR-19a
and miR-21, suggests that their differential expression
modulates PTEN protein levels and the CS or CSL phe-
notype in patients with these syndromes, irrespective of
their PTEN mutation status.
Variable PTEN protein levels were inversely correlated
with miR-19a and miR-21 expression levels in PTEN-muta-
tion-positive patients and, more speciﬁcally, only in pa-
tients with R130X and/or R233X mutations. In patients
with theR335Xmutation, inwhich the relationship among
miRNA expression, PTEN protein levels, and clinical diag-
nosis was absent, seven of ten had classic CS phenotypic
features. This observation suggests that theR335X PTEN ge-
notype strongly inﬂuences phenotype, and indeed, this is
corroborated by the miR-19a- and/or miR-21-independent
overall decreased full-length PTEN protein levels in this
group of patients with the R335X mutation. In contrast,
we believe that differential expression of miR-19a and
miR-21, directly correlated with PTEN protein levels in
R130X and/or R233X mutation carriers, could help modu-
late phenotype beyond the germline mutations.
Similarly, both miRNAs were differentially expressed in
a series of PTEN-mutation-negative patients with CS and
CSL with variable clinical phenotypes and decreased
expression of full-length PTEN protein. Importantly,
decreased expression of PTEN transcript levels was not
observed in these mutation-negative patients, suggesting
that their decreased PTEN protein expression is probably
due to dysregulation at the protein level. Taken together,
our data in both mutation-positive and mutation-negative
patients demonstrate that miR-19a and miR-21 can modu-
late PTEN protein levels. Because PTEN’s sufﬁcient activity
is dependent on its protein levels, perturbation of its
expression can enhance disease progression and facilitate
tumorigenesis.25 Therefore, our data suggest essential roles
for miR-19a and miR-21 in the modulation of the diverse
clinical and molecular phenotypes observed in CS.1146 The American Journal of Human Genetics 82, 1141–1149, May 2008
The identiﬁcation of clear genotype-phenotype correla-
tions has, for the most part, proven elusive in CS and
prompted speculation that other loci contribute to the vari-
able clinical spectrum observed in this syndrome.9,20 Al-
though there is a lack of genetic heterogeneity in CS, recent
studies have suggested that other genetic factors, such as
modiﬁer loci, contribute to disease susceptibility and the
variable phenotypes observed in patients with this disor-
der.1,9,26,27 Interestingly, a study by Freeman et al. demon-
strated that phenotypic differences, including the onset
and incidence of tumor formation, differed among mice
with identical PTEN mutations yet with different genetic
backgrounds.26 These differences correspond well with
the vast clinical spectrum common in patients with CS
and BRRS, suggesting that genetic modiﬁers, which proba-
bly include other genes,miRNAs, and proteins (for example
PICT-1), account for the observed differences in human pa-
tients.28Ourdata strongly suggest thatmiR-19a andmiR-21,
at least in part, contribute to this phenotypic variability.
Interestingly, inaccordancewith this, neithermiR-19anor
miR-21 were differentially expressed in patients with the
BRRS phenotype. Although we interpret this with caution
because of the small number of patients with BRRS included
in our study, this observation suggests that although these
disorders are allelic, their underlying modiﬁers differ. If this
can be replicated in a larger series of patients with BRRS,
then it is tempting to speculate that miR-19a and/or
miR-21 modulation of PTEN leads to CS or CSL, whereas
the absence of thismodulatory inﬂuence, probably together
with other mechanisms, results in the BRRS phenotype.
Although the results of our investigation ofmiR-19a and
miR-21 in patients with CS and CSL are highly suggestive
of their role in these diseases, the precise mechanism by
which these miRNAs are deregulated in these patients is
currently unknown. Both miRNAs localize to chromo-
somal regions in which loss of heterozygosity in sporadic
cancer has been described.27,29–31 However, these loci
have not been genetically linked to CS, CSL, or BRRS. Fur-
thermore, although genetic polymorphisms at miRNA-
binding sites have recently been shown to alter miRNA:tar-
get gene interactions, no genetic alterations have been
identiﬁed in PTEN’s 30 untranslated region (UTR) near
miR-19a’s reported binding site (miR-21’s precise binding
site is unknown).1,3,32 Although these alterations are likely
to result in the loss of miRNA function, it is interesting to
speculate whether genetic variations in PTEN’s 30UTR
further contribute to the variable phenotypic spectrum of
CS and CSL by altering the binding of other potential
miRNAs. To begin to address this question, we recently
screened PTEN’s 30UTR for genetic alterations in a subset
of PTEN-mutation-negative patients with decreased full-
length PTEN protein expression. However, we failed to
identify any sequence differences in these individuals
(Zbuk and Eng, unpublished data). Given these data, we
hypothesize that the differential expression of miR-19a
and miR-21 that we observed in our patients with CS or
CSL probably results from the dysregulation of theirThe Amexpression, perhaps through the oncogenic activation of
miR-19a’s and miR-21’s primary miRNA or through the ab-
errant processing of their mature miRNA. Although the
mechanisms that contribute to the oncogenic activation
of these miRNAs are currently unknown, our data suggest
that, both in the presence and absence of speciﬁc PTEN
mutations, this dysregulation modulates disease pheno-
type. On the basis of our ﬁndings, additional investigation
for better understanding of these potential mechanisms in
patients with CS and CSL is warranted.
Our study is the ﬁrst patient-oriented study to examine
miR-19a and miR-21 expression in CS, CSL, and BRRS.
Along with other, yet to be identiﬁed, genetic modiﬁers,
these miRNAs might contribute to disease susceptibility
and phenotypic modulation and could serve as potential
biomarkers of phenotypic variation associated with each
syndrome. It is our hope that these ﬁndings will improve
our understanding of the pathogenesis of CS, CSL, and
BRRS in patients, both in those with deﬁned germline
PTEN mutations and in those for which traditional muta-
tional-scanning methodologies have been unable to
uncover a genetic etiology. We believe that an improved
understanding of the role of these, and other, modiﬁer
loci in CS, CSL, and BRRS will enable more accurate clinical
and molecular phenotyping and lead to advances in both
the diagnostic and the preventive care afforded to patients
with these and related syndromes as well as with sporadic
neoplasias in which the PTEN pathway is germane.
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One supplemental ﬁgure and one supplemental table are available
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